Last reviewed · How we verify
Metformin, Pioglitazone
This combination reduces blood glucose by increasing insulin sensitivity (pioglitazone) and decreasing hepatic glucose production while improving peripheral glucose uptake (metformin).
This combination reduces blood glucose by increasing insulin sensitivity (pioglitazone) and decreasing hepatic glucose production while improving peripheral glucose uptake (metformin). Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Metformin, Pioglitazone |
|---|---|
| Also known as | Glucophage, Zolid |
| Sponsor | Khyber Medical University Peshawar |
| Drug class | Antidiabetic combination (biguanide + thiazolidinedione) |
| Target | AMPK (metformin); PPARγ (pioglitazone) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that activates AMP-activated protein kinase (AMPK), reducing gluconeogenesis and improving insulin sensitivity in muscle and liver. Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity in adipose tissue, muscle, and liver. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Hypoglycemia
- Weight gain
- Fluid retention / edema
- Lactic acidosis (rare)
- Hepatotoxicity
Key clinical trials
- The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD (PHASE4)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes (PHASE3)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin, Pioglitazone CI brief — competitive landscape report
- Metformin, Pioglitazone updates RSS · CI watch RSS
- Khyber Medical University Peshawar portfolio CI